Ligand ID: IVM


Drugbank ID:
DB00602
(Ivermectin)


Indication:
A broad-spectrum anti-parasite medication. It was first marketed under the name Stromectol® and used against worms (except tapeworms), but, in 2012, it was approved for the topical treatment of head lice infestations in patients 6 months of age and older, and marketed under the name Sklice™ as well. Ivermectin is mainly used in humans in the treatment of onchocerciasis, but is also effective against other worm infestations (such as strongyloidiasis, ascariasis, trichuriasis and enterobiasis).

Get human targets for IVM in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'IVM' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r7y 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.51A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r7y 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.51A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r7y 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.50A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r7z 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.52A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r7z 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.54A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r7z 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.53A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r80 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.54A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r80 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.52A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r80 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.53A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r81 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.56A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r81 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.55A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r81 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.57A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r82 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.52A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r82 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.51A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r82 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.51A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r83 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.53A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r83 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.52A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r83 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.53A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r84 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 13
ILE A 106
ASN A 133
ILE A 136
THR A 292
PHE A 294
1.63A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r84 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.54A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5r84 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.55A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.57A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.56A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.55A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 12
ALA F 944
LEU F 948
LEU F 945
GLN E1180
LEU E 948
1.32A16.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 12
ALA C 944
LEU C 948
LEU C 945
GLN B1180
LEU B 948
1.33A16.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		6 / 10
THR E 941
VAL E 951
LEU D 945
ILE E1179
LEU F 945
ILE F1183
1.76A16.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		6 / 12
THR E 941
SER E 939
SER E 940
ALA E1190
LEU E1186
ILE E 934
1.67A16.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m03 MAIN PROTEASE
(SARS-CoV-2)		5 / 13
ILE A 106
ASN A 133
ILE A 136
THR A 292
PHE A 294
1.63A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		6 / 12
THR E 376
SER E 375
VAL E 401
ILE E 402
ILE E 410
LEU E 425
1.76A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		6 / 12
THR F 376
SER F 375
VAL F 401
ILE F 402
ILE F 410
LEU F 425
1.76A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m3m NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PRO B 118
THR B 149
SER B  52
ILE B 132
GLY B  86
1.50A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m3m NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PRO A 118
THR A 149
SER A  52
ILE A 132
GLY A  86
1.47A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6m3m NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PRO C 118
THR C 149
SER C  52
ILE C 132
GLY C  86
1.50A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 13
ILE B 598
THR B 638
SER B 640
ASN B 641
ILE B 693
1.48A15.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER C1051
ILE C 726
THR C 874
LEU C 938
ILE C 818
1.55A15.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE B 119
GLY B 107
THR B 114
LEU B 229
ILE B 231
1.49A15.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL B 963
LEU B 977
LEU B1004
ILE B 742
LEU B 753
1.11A14.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 13
ILE A 666
PRO A 665
ILE A 692
MET A 697
THR A 696
1.66A15.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
THR C 778
SER C 730
ALA C 771
PRO C 863
LEU C 864
1.34A13.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 13
ILE C 666
PRO C 665
ILE C 692
MET C 697
THR C 696
1.58A15.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE C 666
PRO C 665
ILE C 692
MET C 697
THR C 696
1.58A15.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE A 119
GLY A 107
THR A 114
LEU A 229
ILE A 231
1.53A15.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		6 / 12
THR C 998
ARG C1000
VAL C 976
ALA C 972
LEU C 981
ILE C 993
1.72A14.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
THR B 778
SER B 730
ALA B 771
PRO B 863
LEU B 864
1.38A13.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDI_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
THR B 645
LEU B 611
ILE B 651
LEU B 650
ILE B 692
1.46A13.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B  97
THR A 106
SER A  98
ILE B 108
ILE A 108
1.50A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 13
ILE B  97
THR A 106
SER A  98
ILE B 108
ILE A 108
1.53A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER A1051
ILE A 726
THR A 874
LEU A 938
ILE A 818
1.56A15.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER B1051
ILE B 726
THR B 874
LEU B 938
ILE B 818
1.56A15.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER C1051
ILE C 726
THR C 874
LEU C 938
ILE C 818
1.57A15.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
ASN B 856
LEU B 966
ARG B 995
SER B 974
ILE B 980
1.73A10.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
ASN A 856
LEU A 966
ARG A 995
SER A 974
ILE A 980
1.73A10.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WVD_A_IVMA505_0
(BILE ACID RECEPTOR)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
ASN C 856
LEU C 966
ARG C 995
SER C 974
ILE C 980
1.74A10.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		6 / 12
THR A 376
SER A 375
VAL A 401
ILE A 402
ILE A 410
LEU A 425
1.77A14.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE B 235
ILE B 105
THR B 240
LEU B 229
ILE B 119
1.52A15.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		5 / 13
GLN A 163
ILE A  74
PRO A 162
THR A 165
PHE A 110
1.61A16.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		5 / 12
PRO D 117
THR D 148
SER D  51
ILE D 131
GLY D  85
1.46A16.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		5 / 12
PRO B 117
THR B 148
SER B  51
ILE B 131
GLY B  85
1.46A16.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		5 / 12
PRO C 117
THR C 148
SER C  51
ILE C 131
GLY C  85
1.47A16.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		5 / 12
PRO A 117
THR A 148
SER A  51
ILE A 131
GLY A  85
1.48A16.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B  97
THR A 106
SER A  98
ILE B 108
ILE A 108
1.44A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 13
ILE A  97
THR B 106
SER B  98
ILE A 108
ILE B 108
1.46A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RI5_A_IVMA349_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 13
ILE B  97
THR A 106
SER A  98
ILE B 108
ILE A 108
1.47A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE A  97
THR B 106
SER B  98
ILE A 108
ILE B 108
1.43A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6w4b NSP9
(SARS-CoV-2)		6 / 12
ALA B  31
LEU B  46
LEU B  95
ILE B  92
LEU B 104
LEU B 107
1.70A17.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6w4h NSP16
(SARS-CoV-2)		6 / 12
VAL A6865
ALA A6966
LEU A6959
ILE A6955
LEU A6981
LEU A6978
1.74A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6w4h NSP16
(SARS-CoV-2)		6 / 12
SER A6927
VAL A6865
ALA A6966
ILE A6955
LEU A6981
LEU A6978
1.66A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		6 / 12
SER A6927
VAL A6865
ALA A6966
ILE A6955
LEU A6981
LEU A6978
1.63A20.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		6 / 12
SER A7039
VAL A6807
ALA A6997
LEU A6825
LEU A6848
GLN A6847
1.78A22.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		6 / 12
VAL A6865
ALA A6966
LEU A6959
ILE A6955
LEU A6981
LEU A6978
1.72A20.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6w75 NSP16
(SARS-CoV-2)		6 / 12
SER C7039
VAL C6807
ALA C6997
LEU C6825
LEU C6848
GLN C6847
1.79A21.99
FMT  C7111 ( 3.2A)
None
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6w75 NSP16
(SARS-CoV-2)		6 / 12
VAL A6865
ALA A6966
LEU A6959
ILE A6955
LEU A6981
LEU A6978
1.79A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JAF_A_IVMA503_0
(GLYCINE RECEPTOR
SUBUNIT ALPHAZ1)		6w75 NSP16
(SARS-CoV-2)		6 / 12
SER A6927
VAL A6865
ALA A6966
ILE A6955
LEU A6981
LEU A6978
1.69A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VDH_A_IVMA403_0
(GLYCINE RECEPTOR
SUBUNIT ALPHA-3)		6w75 NSP16
(SARS-CoV-2)		6 / 12
SER A7039
VAL A6807
ALA A6997
LEU A6825
LEU A6848
GLN A6847
1.74A21.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE B 106
ILE B 136
GLY B 109
THR B 292
PHE B 294
1.64A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIF_A_IVMA403_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.56A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RIA_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A 136
GLY A 109
THR A 292
PHE A 294
ILE A 106
1.57A23.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RHW_A_IVMA348_0
(AVERMECTIN-SENSITIVE
GLUTAMATE-GATED
CHLORIDE CHANNEL
GLUCL ALPHA)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A 106
ILE A 136
GLY A 109
THR A 292
PHE A 294
1.58A23.59
None